Pharmaceutical Executive
October 01, 2014
Column
0
0
New research on the role of microbes in fighting disease is transforming the way medicine views bacteria, writes Lee Jones.
October 01, 2014
Column
0
0
Is crowdfunding an attractive alternative to finance pharma and biotech start-ups? Seth R. Ogden and M. Andrew Holtman report.
October 01, 2014
Column
0
0
Companies gain support-and pressure-to deliver new treatments for spreading outbreak.
October 01, 2014
Column
0
0
Pharmaceutical professionals, teams, and organizations can succeed at an elite level by tackling the tough mental challenges of Navy SEAL training.
October 01, 2014
Column
0
0
An escalating political debate over pharma pricing and reimbursement nears the boiling point.
October 01, 2014
Column
0
0
Inter Partes Review can potentially offer a more economical and streamlined litigation strategy for pharma and biotech players, writes David Dalke.
October 01, 2014
Features
0
0
NICE's David Haslam discusses the UK drug watchdog's new challenge in meeting expectations around what quantitative calculations of value mean to patient access today.
October 01, 2014
Features
0
0
Amid the continued surge in M&A activity, Michael Swanick asks, what are the crucial considerations pharma executives should weigh before sitting down at the deals table?